companies

Thirona

Founded 2014
Employees 50+
Primary contact
Toernooiveld 300
6525 EC Nijmegen
Netherlands
Links
https://thirona.eu/
Diseases & Conditions
Sections
Technologies
Founded as a spin-off of Radboud University Medical Center in Nijmegen, Thirona aims to bridge the gap between academic developments in medical image analysis and clinical usability. It does that by creating intuitive and user-friendly products that include state-of-the-art deep learning technology to aid medical specialists in their daily tasks. Specifically, the company has three AI software products focusing on the analysis of thoracic CT scans (LungQ), chest X-rays (CAD4TB), and retinal images (RetCAD). For the Coronavirus pandemic in 2020, Thirona has developed two dedicated AI solutions for X-ray and CT (CAD4COVID). Then in March 2021, it released an AI algorithm that revolutionizes cystic fibrosis care (PRAGMA-AI) to allow for fast, automated analysis of CT scans of patients with CF to detect and quantify lung abnormalities related to CF. Additionally, Thirona offers a certified image analysis service delivering accurate and repeatable measurements from medical images.
Select partners: PulmonX, Parexel, COPDGene, MedQIA, Semmelweis University, Complejo Hospitalario Universitario de Albacete, AWS, Delft Imaging, Fraunhofer-Gesellschaft, Erasmus MC, Maastricht UMC+, HT médica, National Jewish Health, Radboud umc, UMCG, Bernhoven.
Founded 2014
Employees 50+
Primary contact
Toernooiveld 300
6525 EC Nijmegen
Netherlands
Links
https://thirona.eu/
Diseases & Conditions
Sections
Technologies

Funding 💰

Select investors HERAN Partners, Borski Fund, Eurostars

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Strong scientific heritage: As a spin-off of Radboud University Medical Center, Thirona has a strong emphasis on research and clinical validation studies. Its technology has been validated in over 180 scientific papers. 🔗
  • Clinical applications: Thirona's technology is being used in a few different areas, including pharmaceutical drug and treatment development, specialized med-tech solutions for interventional medicine, and to deliver powerful insights for personalized clinical care.
  • Regulatory compliance: Thirona is compliant with the EU's Medical Device Regulation (MDR) and operates under ISO 13485 certification. Also, its products have CE marks and have been approved by the FDA, as well as regulatory bodies of New Zealand and South Korea.
  • Diverse team: The company's team includes people from 14 nationalities, 8 of which hold a PhD. Also, 80% of the staff is engaged in R&D activities. 🔗

Video ▶️

Quotes 💬

“
In cooperation with Thirona, we can offer Pharma and Med-Tech companies the most advanced and well validated quantitative measurements tailored to the needs of each clinical trial.
— Clinical Research Organization, United States
“
The unique combination of medical and technical knowledge, and Thirona's focus on real clinical problems, allows us to innovate our product faster and with higher performance.
— Multinational MedTech Company, The Netherlands
“
Thirona's AI solutions provide highly precise quantitative information of the lungs which is of invaluable importance for planning complex bronchoscopic interventions in our clinic.
— Prof. Interventional Pulmonology, The Netherlands
“
By tapping into the large market of non-oncologic lung diseases and through unparalleled innovation and high scalability of the platform, Thirona is poised to further strengthen its position as category leader in the market of image analysis. We at HERAN Partners are committed to supporting Thirona's growth plans and provide them with capital, network, and expertise in global commercialisation.
— Katleen Vandersmissen, Managing Partner at HERAN Partners 🔗
“
The combination of profound inhouse medical knowledge and deep learning expertise provides a unique technology platform in the field of medical image analysis. The robust scientific approach and focus on genuinely value adding propositions underpins the leadership of Eva and Guido, positioning Thirona to accelerate growth in a fast-expanding market. We are pleased to add Thirona to our portfolio as the third medical company. We look very much forward to supporting Eva and the management team in their personal and organisational growth.
— Bertrand van Leersum, Investment Director at Borski Fund 🔗
Last update: April 26, 2023